Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression.

Hurel, S J; Harris, P E; McNicol, A M; Foster, S; Kelly, W F; Baylis, P H

Hurel, S J; Harris, P E; McNicol, A M; Foster, S; Kelly, W F; Baylis, P H.

Affiliation

Hurel SJ; Department of Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.

J Clin Endocrinol Metab ; 82(9): 2962-5, 1997 Sep.

Article in En | MEDLINE | ID: mdl-9284727

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Gene Expression; Pituitary Neoplasms/drug therapy; Pituitary Neoplasms/secondary; Prolactinoma/drug therapy; Proto-Oncogenes; Antineoplastic Agents, Hormonal/administration & dosage; Antineoplastic Agents, Phytogenic/administration & dosage; Cabergoline; Carboplatin/administration & dosage; Ergolines/administration & dosage; Etoposide/administration & dosage; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Magnetic Resonance Imaging; Middle Aged; Octreotide/administration & dosage; Pituitary Neoplasms/diagnosis; Prolactinoma/diagnosis; Prolactinoma/genetics; Proto-Oncogene Mas; Somatostatin/analogs & derivatives; Treatment Failure

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Proto-Oncogenes / Prolactinoma / Antineoplastic Combined Chemotherapy Protocols / Gene Expression Type of study: Diagnostic_studies / Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: J Clin Endocrinol Metab Year: 1997 Document type: Article

Search on Google

XML

PubMed Links